12:40 PM EDT, 09/27/2024 (MT Newswires) -- Cytokinetics ( CYTK ) said Friday that findings from a new analysis of phase 3 trial of aficamten, its investigational drug for treating heart muscle thickening, showed beneficial changes.

Cytokinetics ( CYTK ) said the analysis showed about 84% of patients treated with aficamten "experienced favorable effects in at least one of the five domains, compared to 39.3% of patients on placebo."

"The results demonstrated favorable remodeling across multiple domains, including cardiac structure and function, electrophysiology and biochemistry," said Dr. Stephen Heitner, vice president and head of clinical research at Cytokinetics ( CYTK ).

The company conducted a virtual presentation of the additional data at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions.

Price: 52.19, Change: -0.44, Percent Change: -0.84